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Abstract
Purpose Osteochondral allografts (OCA) consist of a layer of hyaline cartilage and a layer of underlying bone. They are 
used to repair combined defects of articular cartilage and bone. Such defects often occur in people far too young to have knee 
arthroplasty, for whom the main alternative to OCA is conservative symptomatic care, which will not prevent development of 
osteoarthritis. The aim of this report was to assess the cost-effectiveness of osteochondral allograft transplantation in the knee.
Methods Systematic review of evidence on clinical effectiveness and economic modelling.
Results The evidence on osteochondral allograft transplantation comes from observational studies, but often based on good 
quality prospective registries of all patients having such surgery. Without controlled trials, it was necessary to use historical 
cohorts to assess the effect of osteochondral grafts. There is good evidence that OCA are clinically effective with a high graft 
survival rate over 20 years. If an OCA graft fails, there is some evidence that revision with a second OCA is also effective, 
though less so than primary OCA. Economic modelling showed that osteochondral allograft transplantation was highly 
cost-effective, with costs per quality adjusted life year much lower than many other treatments considered cost effective.
Conclusions Osteochondral allograft transplantation appears highly cost-effective though the cost per quality adjusted life 
year varies according to the widely varying costs of allografts. Based on one small study, revision OCA also appears very 
cost-effective, but more evidence is needed.
Level of evidence II.
Keywords Allografts · Osteochondral · Systematic review · Cost-effectiveness
Introduction
Osteochondral allografts (OCA) replace not only the articu-
lar cartilage but also a layer of underlying bone. The articu-
lar cartilage is the same thickness as the patient’s own (about 
4 mm), and the living chondrocytes are too embedded in 
the cartilage to trigger a significant immune response. The 
allograft can, therefore, almost exactly replace a cartilage 
and bone defect in the host’s knee.
Options are limited for a patient with a defect in both 
the cartilage and the underlying bone (osteochondral 
defect), most often due to trauma or osteochondritis dis-
secans (OCD) [26]. It has been shown in historical studies 
[41, 63] that patients with OCD, particularly ones where 
the fragment has been removed, have a very high risk of 
future osteoarthritis and poor knee function. Most of these 
patients, as well as those with traumatic lesions, are young 
and active, and knee arthroplasty is rarely indicated. A total 
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knee arthroplasty (TKA) does not restore full knee function 
for most young patients. In older patients, a unicompart-
mental knee arthroplasty may offer slightly better rates of 
return to sporting activities [16], but knee arthroplasty rarely 
results in normal knee function. A TKA in a young patient 
will usually fail in their lifetime, resulting in a need for fur-
ther arthroplasty. Bayliss et al. [5] reported that the lifetime 
risk of revision for a TKA was 35% for men and 20% for 
women having their primary procedure in their early 1950s. 
Data on the risk of revision for patients younger than this 
are sparse as it is rarely performed, but the risk of revision is 
thought to be exponentially higher, due to increased activity 
as well as longer life expectancy.
Management of the “deep OCD” has been a challenge. 
Apart from OCA, other options that have been tried include 
a morcellised bone graft in the base covered with an autolo-
gous chondrocyte implantation (ACI) patch (more expen-
sive than OCA), and synthetic grafts. Mosaicplasty can be 
used to treat osteochondral lesions but donor site morbidity 
limits this to small lesions. Cartilage restoration techniques 
such as microfracture and ACI do not replace bone defects 
and do not do well when the underlying bone is damaged. 
Some symptoms may be relieved by an unloading osteotomy 
[46] but this does not resolve the underlying intra-articular 
damage.
McCulloch et al. [46] have set out the advantages of 
OCA: the ability to repair larger and deeper defects with 
mature hyaline cartilage, to resolve the underlying bone 
defect, and to do so in a single procedure. Briggs et al. [7] 
note that in the past, OCA had been regarded as a salvage 
procedure when previous surgery failed, but reported good 
results in a series of 55 patients who had not had previous 
surgery. They argue that OCA can be a useful first-line treat-
ment especially in patients with large defects. In their case 
series, the average defect size was 9.6 cm2.
Bugbee et al. [9] provide an overview of OCA in which 
they note that despite proof of concept evidence going back 
to the 1980s, there was little use of OCA until the late 1990s, 
and even then it was carried out mainly in a few specialised 
centres with local tissue banks.
Evidence: reviews
Seven recent systematic reviews were identified that covered 
the use of OCA in the knee, some as part of wider reviews, 
including other interventions. Quality assessment is reported 
in the Supplementary file, Table 1.
A review by Salzmann et al. [56] was concerned with the 
use of particulated juvenile articular cartilage rather than 
discrete allografts and was omitted. A review by Seow et al. 
[57] on extracellular matrix and particulate cartilage allo-
grafts was also excluded. The Cochrane review by Gracitelli 
et al. [30] was not included because no studies of OCA were 
included.
The studies included in the reviews varied, reflecting their 
different aims. Assenmacher et al. [3] included only studies 
with a minimum of 9 years of follow-up. Campbell et al. 
[11] focused on return to sport in athletes and included stud-
ies with a minimum follow-up of 12 months, while Krych 
et al. [35] included studies if they reported return to sport 
outcome measures. De Caro et al. [17] looked at fresh allo-
grafts for large lesions and only included studies with at 
least ten participants and 1-year follow-up. Rosa et al. [37] 
were interested in repairs of failed cartilage repair but also 
reviewed failure rates in the primary repairs. Chahal et al. 
[12] included studies with a minimum sample size of 10, a 
minimum follow-up of 12 months and studies that were of 
allograft transplantation alone or in combination with other 
techniques including meniscal allograft transplantation and 
osteotomy.
The conclusions of the reviews are shown in Supplemen-
tary file Table 2. Assenmacher et al. [3] reported that 75% of 
patients had good results at mean of 12.3 years after OCA, 
with the largest drop in graft survival being at 15–20 years, 
in patients with mean age 30 years at OCA. De Caro et al. 
[17] also reported good results, in studies using fresh OC 
grafts, but identified cost as the main barrier. Chahal et al. 
[12] also reported good results with fresh or fresh-frozen 
grafts.
Evidence: primary studies
Some of the best evidence comes from groups that have 
built up large cohorts of patients over many years. The sup-
plementary file Table 3 gives summary details of these and 
other OCA studies.
Gross et al.
The earliest reports, with longest follow-up, come from the 
Mount Sinai Hospital, Toronto, group of Allan Gross and 
colleagues. Their first OCA in the knee was done in 1972. 
In Gross et al. [31], they report results in femoral condyle 
and tibial plateau separately, for OCAs done in 1972–1995, 
with mean follow-up of 10 years. In 60 femoral OCAs, graft 
survival was 95% at 5 years, 85% at 10 years, and 74% at 
15 years. Mean age at OCA was 27 years (range 15–47). In 
12 patients, OCA failed, with 9 having TKA. In 65 tibial 
OCAs, mean age at OCA was 42 (range 26–69) years, and 21 
failed and had TKA at mean follow-up of almost 10 years. 
Graft survival was 95% at 5 years, 80% at 10 years, 65% at 
15 years, and 46% at 20 years.
Drexler et al. [19] report results in a subgroup of 27 
consecutive patients who had combined distal femoral 
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osteotomy and tibial OCA following failed tibial plateau 
fracture, from 1981 to 2005. Median age was 41 (range 
17–62) years. There were good improvements in clini-
cal scores, and graft survival was 89% at 10 years, 71% at 
15 years and 24% at 20 years.
The longest follow-up from the group was by Raz et al. 
[53], after femoral condyle OCA, with 59% graft survival 
at 25 years.
Bugbee et al.
William Bugbee et  al. have built up one of the biggest 
cohorts of people who have had OCA, with over 800 
patients. In an overview in 2016 [9], they provide data on 
results in 527 knees in 467 patients, mean age 34 (range 
14–68) having OCA for cartilage injury (35%), OCD (30%), 
cartilage degeneration (12%), osteonecrosis (8%), and early 
osteoarthritis (OA) (6%).
Results varied by aetiology and history. The best results 
were seen in patients who had had osteonecrosis (89% graft 
survival at mean follow-up 5.6 years, range 2–20 years, and 
85% at 12 years) [9, 55] or after previous cartilage injury 
(98% at 12 years). Good results were also seen after OCA 
in patients under 18 year of age with 90% graft survival at 
10 years, with good improvement in symptom scales [51]. 
Results were not as good in osteoarthritis (41% at 12 years) 
and in bipolar injuries (“kissing lesions”) with 46% failures 
rate in 48 knees [47].
However, for many with OA, the alternative (if they were 
old enough—many would not be, given mean age 34) would 
be knee arthroplasty (KA). In those patients, OCA of a fem-
oral hemicondyle might provide at least temporary relief 
of symptoms pending later Knee arthroplasty, and function 
would be expected to be better than after knee arthroplasty 
as the cruciates and menisci (if intact) are retained, meaning 
knee kinematics and possibly proprioception are preserved.
OCA was largely a salvage procedure in a tertiary centre. 
Eighty-eight percent of patients had had previous surgery, 
with an average per patient of two previous procedures. 
Briggs et al. [7] report that results were better in patients 
who had not had previous surgery, with OCA survival 
almost 90% at 5 year and 75% at 10 years, and 61% having 
some further procedures. Gracitelli et al. [29] reported that 
OCA after failed previous procedures (including microfrac-
ture, mosaicplasty, ACI), in 164 knees, was less successful, 
with graft survival 82% at 10 years and 75% at 15 years—
but still very successful, and accompanied by significant 
improvements in symptoms. In another study, Gracitelli 
et al. matched 46 patients who had had previous subchon-
dral bone marrow stimulation procedures with 46 who had 
OCA as primary procedure [28]. At 10 years of follow-up, 
graft survival was similar (86% and 87%) but almost twice 
as many of the prior marrow stimulation group required 
subsequent procedures (including arthroscopic debridement) 
as the primary OCA group (44% versus 24%).
Tirico et al. [62] examined results of OCA by size of 
condylar defect in 156 knees from 1998 to 2014. The aver-
age graft area was 6.4 cm2, range 2.3–11.5 cm2. Most (62%) 
patients had had OCD. Overall graft survival was 97% at 
5 years and 93.5% at 10 years, with no difference by graft 
size, whether measured as absolute area or relative to knee 
size. Outcomes were broadly similar but benefits were 
greater in large defects (> 8 cm2).
The size of the cohort allows subgroup analysis. Cameron 
et al. [10] report the results of 29 OCA grafts of the femo-
ral trochlea alone (1993–2011) with graft survival 100% at 
5 years and 92% at 10 years, and good improvements in 
clinical scores.
Gracitelli et al. [26] report the results of isolated patel-
lar OCA in 28 knees from 1983 to 2010. Results were not 
as good as in some other sites, with 78% graft survival at 
10 years and 56% at 15 years.
Horton et al. [33] report results in 33 patients who had 
a second OCA after the first failed. At 10 years, 61% of the 
second OCAs survived, with good symptomatic improve-
ment. The 39% of grafts that failed did so at mean follow-up 
of 5.5 years.
Nielsen et  al. [52] reported a high level of return to 
sport after OCA, with 79% returning to a high level of 
performance.
Cole et al.
Another group with considerable experience is the Rush 
University group in Chicago, Brian Cole and colleagues. 
McCulloch et al. [46] concluded that OCA was a safe and 
effective procedure, in a small group of 25 patients in the 
years 2000–2003. They had had several previous procedures 
(mean of 2.3 operations), and represented a tertiary refer-
ral group. There was good improvement in Lysholm scores, 
from 39 to 67 (p < 0.0001).
A series of articles from Frank et al. [22–24] reported 
experience in later years, 2003–2014, in 180 consecutive 
patients with minimum follow-up of 2 years. Graft survival 
was 87% at 5 years. There was no difference in failures rates 
by age—13% in over 40 s, and 16% in under 40 s—or by 
gender. Concomitant meniscal allograft transplantation 
(MAT), performed in 36% of patients, caused no problems.
Williams et al.
Another study comes from the New York Hospital for 
Special Surgery group, with data prospectively collected 
by Riley Williams and colleagues from 1999. They have 
provided a series of papers looking at subgroups, showing 
that results of OCA are no worse in patients who have had 
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anterior cruciate ligament reconstruction (ACLR) [64] or in 
those with Body Mass Index (BMIs) over 30 (graft survival 
83% at 5 years) [49]. They also found that results in patients 
aged over 40 (mean age 48, range 40–63 years) were also 
good, with graft survival 73% at 4 years [65].
Williams et al. [66] have treated elite and other high-
performance athletes, and Balaz et al. [4] and Krych et al. 
[36] have reported high proportions returning to high level 
performance.
While OCA is regarded as the treatment of choice as 
a salvage procedure, it is not clear why it was originally 
regarded by some as only a salvage procedure, given its high 
success rate. In the Gracitelli et al. study [28] comparing 
those with and without prior procedures, mean age 27 years, 
both groups did well, with 11% failure in those with no pre-
vious repair attempts and 15% in the previous repair group. 
By 10 years, survival was no different. Gracitelli et al. [28] 
attribute this to the technique used in OCA, wherein 3–8 mm 
of subchondral bone is removed and replaced, including the 
layer damaged by previous procedures.
Cotter et al. [14] report a series of patients who had had 
an unsuccessful previous repair attempt after OCD (mostly 
microfracture, open fixation and loose body removal), and 
then had OCA. At a mean follow-up of 7.3 years, 82% had 
returned to sport and were satisfied with the results of sur-
gery. This study was not included in a systematic review by 
Lamplot et al. [38] of treatment of failed cartilage repairs. 
Lamplot et al. found three studies of the use of OCA after 
failed repairs, mainly microfracture, and noted that, unlike 
with ACI, previous MF did not reduce the success rate of 
OCA [38].
Return to sport after OCA was also reported by Nielsen 
et al. [52] in a series of 142 patients, about half of whom 
were highly competitive athletes, with the rest described 
as “well-trained and frequently sporting”. 75% returned to 
sport, including at strenuous levels.
The poorest return to previous activities was reported by 
Shaha et al. [58] in US soldiers. They found that 42% (16/38) 
were unable to return to full military duties after OCA, espe-
cially if their military activity included combat.
The aims of OCA repair are to eliminate symptoms, 
restore the normal biomechanics in the knee, and prevent 
the development of osteoarthritis and the need for knee 
arthroplasty.
Historical controls
The most serious limitation in the evidence is the absence of 
control groups. No RCTs of OCA were found. The studies 
are mostly before and after studies, which do not give data 
on the effectiveness of OCA over no, or only non-surgical 
treatment. It was, therefore, necessary to rely on observa-
tional studies of untreated osteochondral or chondral defects, 
often historical. This is an inherent risk of bias in such com-
parisons, but it was necessary to make the best use of what 
data are available.
Messner and Maletius [48] reported progression of OA 
in 28 athletes with symptomatic chondral defects over a 
14-year period, with joint space narrowing.
A considerable proportion of people with osteochondral 
defects have or had OCD. The natural history of this has 
been reported in several studies. Linden [41] followed up 67 
joints in 58 patients for a mean of 33 years. These patients 
had had onsets in childhood (mean age 13) or as adults 
(mean age 29), with 80% of lesions on the medial condyle. 
Internal fixation was not used, and most had arthrotomy and 
removal of fragments. The results were different for adult 
and childhood onsets. At mean follow-up of 33 years, none 
of the childhood onset cases had severe OA. Of the adult 
onset cases, over 60% (33/53) had severe OA. The pain of 
OA came on about 20 years after injury.
Anderson and Pagnani [1] reported that of 19 patients 
who had OCD fragments removed, 8 had severely abnor-
mal International Knee Documentation Committee (IKDC) 
scores after as little as 5 years (range 5–20 years). Unlike 
in the Linden study, no significant differences were seen 
between those patients whose OCD developed before growth 
ended. Twyman et al. [63] also reported poor outcomes in 
a series of 22 patients with onset of OCD before skeletal 
maturity. After a 34-year follow-up, a third had moderate 
or severe OA.
A natural history study of articular cartilage defects was 
carried out by Shelbourne et al. [59]. The defects had been 
incidental findings in people having ACL reconstruction. 
Patients with cartilage defects were matched with others 
having ACL reconstructions but who had no articular car-
tilage defects. At a mean follow-up of 6 years, there was a 
little difference in symptom scores. This suggests that OA 
takes time to develop, but mean defect size in this cohort 
was only 1.7 cm2.
Without OCAs, many of these patients are destined to 
develop early and severe OA. As noted by Heir et al. [32], 
some already have considerable impairment in quality of 
life. Treatment would be by analgesics and rehabilitation 
such as physiotherapy.
Survival of OCA grafts
The Assenmacher review [3] summarised mean long-term 
survival from three studies as
5 years = 94%
10 years = 84%
15 years = 71%
20 years = 45%.
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Sherman et al. [60] reviewed five studies and reported 
survivals of 85–100% at 5  years, 71–97% at 10  years, 
74–76% at 15 years and up to 66% at 20 years. However, 
they noted poorer results in people with pre-existing OA, 
and in patello-femoral lesions.
Both Sherman et al. [60] and Rosa et al. [54] regard OCA 
as the best option after failure of ACI, microfracture and 
mosaicplasty.
The longest term study is by Raz et al. [53] with 59% 
graft survival at 25 years.
Even when OCAs fail, most of the failures occur after a 
considerable time, such as after 15 years. They can, there-
fore, postpone knee arthroplasty until an age range where 
the TKA may be more acceptable to the patient and may not 
need to be revised. Some patients may have unicompartmen-
tal KA first, but which may later be revised to TKA.
Economic analysis
The knee model starts from the decision to insert OCA. It 
was assumed that any patients with sufficient malalignment 
to require osteotomy would have that done first (or at the 
same time). So the arms of the study are intervention with 
OCA and non-surgical care.
Failures after OCA arm can be considered for a second 
OCA, or can go down the same pathway as the no-surgery 
group. However, most will do well, with over half still suc-
cessful at 15 years. Some will then fail, but patients may 
then have reached the age at which knee arthroplasty is 
acceptable. So the effect of OCA, over a 30-year period, 
is to avoid KA in many, and to delay it in others. The delay 
reduces the likelihood of revision TKA being required.
Modelling
Non-surgical care will include symptomatic relief with anal-
gesics, and may also include physiotherapy. The underly-
ing osteochondral defect will not be affected by these, and 
patients will progress to osteoarthritis and in due course, 
knee arthroplasty. If symptoms become severe, they may 
be considered for earlier than usual knee arthroplasty, with 
the acceptance that the initial arthroplasty will not last a 
lifetime, and that subsequent revision(s) will be required.
A major driver in the modelling is knee arthroplasty costs, 
which depend on the number of arthroplasties per patient per 
lifetime. Bayliss et al. [42] used the UK Clinical Practice 
Research Datalink to examine arthroplasty revision rates 
by age of first arthroplasty. People aged 70 or over at first 
TKA had only about a 5% chance of needing a revision in 
their lifetime, but people younger at TKA had a much higher 
chance, with the highest reported being a 35% revision rate 
of TKA in men aged 50–54 years. The rate amongst women 
was about 20% lower. The mean duration in these men from 
TKA to revision was only about 5 years, meaning that a 
second or third TKA revision was likely.
The higher revision rate in men may be linked with return 
to sport. In a systematic review, Witjes et al. [67] found 
that most of 3261 men had returned to sporting activities 
3 months after a TKA. Dagneaux et al. [16] conclude that 
most people can return to intermediate activities but that 
return to sport should be gentle and progressive.
So if OCA can avoid revision in most people, or postpone 
it in others, it can mean that first TKA is at least delayed, 
and that the need for revision TKA is reduced. For example, 
if OCA in a 40 year-old can give a good result for 20 years, 
first TKA at age 60 is much less likely (about 15%) to need 
to be replaced than a first TKA at age 50 (35%).
The evidence on TKA under age 50 is sparse, and as 
noted by Lonner et al. [42], most TKA in the under 1950s is 
done for rheumatoid arthritis (RA), not OA, and so not rel-
evant to this review. (RA is a systemic disease and if some-
one has severe RA with TKA at, say, age 40, they are likely 
to have other joints affected and to be physically less active, 
and unlikely to be taking part in activities that confer a high 
risk of revision being required.) Lonner et al. reported the 
results of TKA in 32 patients with OA, who had the proce-
dure under 40 years of age. Good results were seen in 91% 
(no revision needed) or 87% (either revision or radiological 
evidence of loosening) at mean follow-up 8 years (range 
5–17 years). The TKAs were done from 1982 to 1994. How-
ever, the 9% revision rate at 8 years may not be sustained at 
longer durations.
A proportion, perhaps 30%, will have UKA, because they 
have single-compartment OA. However, the use of UKA 
appears to vary regionally and internationally.
Assumptions for modelling
For survival, the figures from Familiari et al. [21] were used 
because they are based on a number of studies. (Note that 
these results are not as good as in some individual studies). 
Mean survivals:
87% at 5 years
79% at 10 years
73% at 15 years (range 56–84%, five studies)
68% at 20 years (range 66–69%, two studies).
One study [53] reported 59% survival at 25 years.
In the base-case, it was assumed that no one has TKA 
before age 55, so if OCA fails, they will have conservative 
symptomatic treatment till age 55. In practice, some people 
may have TKA at age 50, whereas others might postpone it 
till age 60.
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For the no-surgery arm, it was assumed that they have 
few symptoms for 10 years, on average, because there are 
two main groups, those with OCD in whom symptoms may 
not appear for many years, and those with chondral injuries 
with poor underlying bone structure, who present with pain. 
They will need non-surgical care till they become eligible 
for TKA at age 55.
From ages 40 to 55, they will have increasing disutility 
from OA. By about age 60, at least 60% will have had TKA, 
whereas by age 60, only at most 22% of the OCA group will 
have had TKA, assuming that all graft failures do have TKA.
For cost purposes, it was assumed that fresh allografts 
were used, and that small lesions (under 2 cm2) would not 
receive OCA, but would be treated by, e.g. mosiacplasty [in 
line with the UK Surgeons Consensus document on ACI and 
the National Institute for Health and Care Excellence (NICE) 
guidance on ACI]. In the base-case, the cost of an allograft 
was taken from the JRF Ortho price list, as £12,850 (http://
jrfor tho.org/). A lower cost was used in a sensitivity analysis.
OCA revisions
OCA repairs of osteochondral defects are usually success-
ful, but a proportion fails as reported earlier. After failure 
of first OCA, it was assumed that a second OCA would be 
offered, with 10-year survival poorer than after primary, but 
still around 50% at 10 years. There are few studies on revi-
sion OCA.
In the Horton et al. [33] study, all patients had revision 
of previous OCA. Some other studies include a few patients 
having revision OCA (Emmerson 5 OCAs [20], Gortz 3 
[26], Levy 15 [40], and Meric 3 [47]) after failed primary 
OCA, but do not give results of these separately, probably 
because of the small numbers.
So the best evidence on the success of second OCA after 
failure of the first OCA comes from the Horton study of 
33 patients [33]. Failure was defined at progression to KA. 
The mean age at first OCA was 33 years (range 16–64) with 
failure in 39% of second OCA at mean 5.5 years. Failure 
was common in older patients so mean age at failure was 
45 years. All of the 13 failures had knee arthroplasty [12 
TKA, 1 unicompartmental (UKA)].
It was assumed that revision OCA was less effective than 
primary OCA, but 61% got good results, and the alternative 
would have been continuing symptoms and non-surgical 
care, or arthroplasty at a much younger than ideal age.
Failure of revision OCA was linear over the first 12 years 
with survival at year 12 about 48%. So each year, approxi-
mately 4% fail. After that, Horton et al. [33] report no further 
failures but numbers by then are very small.
This study, though small and from a centre of excellence, 
is the best data available currently on revision OCA. The 
cost-effectiveness was modelled using the same model as 
for primary OCA, but applying different transition probabili-
ties. However, one problem is what to assume after year 12. 
One solution is that after year 12, the same failure rates as 
in primary OCA of about 1.4% per annum can be applied.
An alternative would be to assume no further failures 
(which is what Horton et al. [33] reported), but that seems 
over-optimistic.
The results of this modelling must be treated with caution 
because of the small number of patients reported by Horton 
et al. [33], but it is the best data available.
The aim of this analysis is to determine whether OCA 
is cost-effective compared to current standard practice (no 
OCA), as primary treatment for patients who have a defect 
both in the cartilage and the underlying bone.
Patients who have had OCA can have a number of 
outcomes:
• Permanent success—where symptoms are relieved, and 
no TKA is necessary.
• Failure, in the short term treated symptomatically with 
analgesics; and in the medium term developing OA 
treated symptoms with non-surgical care (analgesics 
and physiotherapy); and in the longer term have a knee 
arthroplasty.
Assumptions included a mean age at initial osteochondral 
injury of 30 years, that patients will develop symptomatic 
osteoarthritis around the age of 40, and might have a knee 
arthroplasty later, but not until they are aged 55 years or 
above.
Model structure
A Markov model was developed within Microsoft  Excel® 
and was considered the most appropriate to determine 
whether OCA would postpone or avoid knee arthroplasty in 
the longer term for patients with a defect both in the articular 
cartilage and the underlying bone. The different health states 
for the model are shown by the ovals. The model shows all 
the transitions that can happen between the different health 
states by the direction of the arrows. The little loop arrows 
in the left hand corner of the ovals (recurring arrow) means 
that a patient can stay in that health state for more than one 
cycle, and perhaps indefinitely, until they die.
Figure 1 shows the model structure for patients who have 
no OCA (standard care). The starting point of the model is 
patients aged 30 years. These patients manage their pain 
with analgesics. When they get to around the age of 40 years, 
they begin to develop symptomatic OA, which they will 
manage with a non-surgical care package of analgesics and 
physiotherapy. When the patient turns 55 years of age, they 
may choose to have a knee arthroplasty (see Fig. 3). From 
all health states, patients can die.
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Figure 2 shows the model structure for patients who have 
an OCA transplantation. The starting point of the model is 
patients aged 30 years who have received an OCA trans-
plantation. After the OCA, patients can then move either 
to a successful health state where symptoms are relieved 
or to failure health state where symptoms are not relieved. 
For those patients who move to the successful health state, 
some patients can remain there permanently, or over time 
the OCA can fail and they then move to the failure health 
state. Patients whose symptoms are not relieved manage 
their pain with analgesics. When they get to around the 
age of 40 years they begin to develop symptomatic OA, so 
they will manage their OA symptoms with a non-surgical 
care package, which includes analgesics and physiotherapy. 
When the patient turns 55 years of age, they may choose to 
have a knee arthroplasty (see Fig. 3). From all health states, 
patients can die.
Patients over the age of 55 can have a knee arthroplasty 
or non-surgical care. A patient can move to first knee 
arthroplasty from the symptomatic OA health state when 
they reach the knee arthroplasty age range (see Fig. 3). The 
first knee arthroplasty can be either a UKA or TKA, but 
all subsequent arthroplasties are assumed to be TKAs. The 
first knee arthroplasty can be a permanent or temporary 
success, so the patient moves to the successful first knee 
arthroplasty health state, or the arthroplasty can fail over 
time, so they move to the failure of first knee arthroplasty 
health state, from which patients can choose to have another 
knee replacement or to have no further knee arthroplasty. 
The second knee arthroplasty can be a permanent success, 
or a temporary success, and they move to the failure of fur-
ther knee arthroplasty health state, from which they can 
choose to have no further knee arthroplasty and or to have 
another (third) knee arthroplasty. Patients who move to the 
no further knee arthroplasty health state choose not to have 
another knee arthroplasty and stay in this health state. From 
all health states patients can die. From the knee arthroplasty 
Fig. 1  No OCA model structure
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health states, there is a slight risk of mortality associated 
with the knee arthroplasty.
Base‑case analysis
For the base-case analysis, the cost-effectiveness of OCA 
was compared with no OCA using a lifetime horizon (i.e. 
patients can live to 100 years) with a cycle length for the 
model set at 1 year and transitions between each health state 
occurring at the end of each cycle. A hypothetical cohort 
of 1000 patients with a defect both in the cartilage and the 
underlying bone with a starting age of 30 years is followed. 
No differentiation was made by gender. The analysis is con-
ducted from the perspective of the UK National Health Ser-
vice (NHS) and personal social services (PSS). All costs 
are in pounds sterling (£) in 2016/2017 prices. Health out-
comes are measured in quality-adjusted life years (QALYs), 
based on their likelihood of the cohort surviving each cycle. 
Results are expressed as incremental cost per QALY gained. 
An annual discount rate of 3.5% is applied to both costs and 
outcomes in line with recommended guidelines.
Fig. 2  OCA model structure
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Model inputs
Transition probabilities
For the base-case analysis, annual transition probabilities 
were based on data derived from the literature and assump-
tions from clinical experts. OCA survival (of allograft) 
was based on rates provided in the systematic review by 
Familiari et al. [21]. The mean 5, 10, 15 and 20 year sur-
vival rates were 86.7%, 78.7%, 72.8% and 67.5%, respec-
tively [21]. Longer term graft survival was based on a study 
by Raz et al. [53], who reported a 25-year survival rate of 
59.0%. These points were fitted onto a graph to check the 
plausibility of the survival curve and then calculated annual 
transition probabilities from this survival curve to use in 
the economic model. Once they move out of the successful 
health state and into the failure/non-surgical care/OA arm, 
it was assumed that patient will stay there until they get to 
the knee arthroplasty age.
For the No OCA arm, patients remain in the non-surgical 
care/OA arm, until they get to the knee arthroplasty age.
When the patient turns 55 years (bearing in mind that 
by this point, they would on average be 25 years on from a 
diagnosis of OCD, so severe OA will be common), it was 
Symptomatic OA
First knee
arthroplasty
Successful first
knee arthroplasty
Failure from first 
knee arthroplasty
Further knee
arthroplasty
No further knee
arthroplasty
Successful further  
knee arthroplasty
Failure from 
further knee
arthroplasty
Fig. 3  Model structure for knee arthroplasty
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assumed that 40% will remain in the OA health state, 30% 
have a UKA and 30% have a TKA.
Transition probabilities for success and failure for patients 
who needed knee arthroplasties or knee arthroplasty revi-
sions were derived from two studies: Dong and Buxton [18] 
and Gerlier et al. [25].
Utilities
For patients who move to the following health states, suc-
cessful health state or no TKA health state, the utility values 
for the UK general population were used and adjusted this 
using an age-related utility decrement [2].
For those patients who move to the failure/non-surgical 
care health state, a utility value of 0.721 was used based 
on non-obese patients who had knee pain and were aged 
between 25 and 44 years from Losina et al. [43]; the authors 
modelled different pharmacological regimens for knee oste-
oarthritis prevention.
For patients who developed osteoarthritis, a utility value 
of 0.645 from Mari et al. [45] was used, which was based on 
patients who had knee osteoarthritis with a non-pharmaco-
logic option (physical therapy).
Mean utility values are the same for knee arthroplasties 
after OCA or no OCA and are based on utility values used 
in our previous report [50]. Before the first knee arthroplasty 
(UKA or TKA), patients are assumed to have the same util-
ity value (0.615). This value was based on an average of 
two utility values: (1) the EQ-5D index score at baseline 
pre-operatively for knee arthroplasty (0.51) [34] and (2) an 
estimate for TKA operation for knee problem (0.72) [18]. 
For patients who move to the successful first TKA or UKA 
health state, a utility value of 0.780 was used [18]. This 
value was estimated from the generic Knee Society Score 
scale and was applied to the normal health state after pri-
mary TKA. If patients move to the successful further TKA 
health state, it was assumed that they will have the same util-
ity value as if it was a first TKA. Gerlier et al. [25] was used 
to obtain two further utility values: (1) for patients for whom 
TKA has failed, and a further TKA is required, the value 
was based on the failed TKA/revision health state (0.557) 
and (2) for patients who move to the no further TKA health 
state value, this was based on patients who had no clinical 
success 5 years after surgery (0.691).
Resource use and costs
All unit costs are presented in pounds sterling (£) in 2016/17 
prices. The cost of OCA transplantation includes the costs 
of the OCA (femoral condyle) graft and the implantation. 
The implantation cost was based on the costs for major knee 
procedures for non-trauma patients who are 19 years and 
older with a CC score 0–1 which was obtained from the 
NHS reference costs [27]. Before a patient receives the OCA 
transplantation, they have an outpatient appointment with 
an orthopaedic consultant. Cost includes three follow-up 
outpatient clinic visits as most patients are seen between 
6 weeks and 3 months post-operation and also eight visits 
to see a hospital physiotherapist where each session lasts 
30 min (see Table 1).
Patients with OA will receive non-surgical care consisting 
of analgesics, paracetamol and ibuprofen, and physiotherapy, 
and eight visits to see a hospital physiotherapist where each 
session lasts 30 min. Medication costs were obtained from 
the British National Formulary [8].
The cost for a first knee arthroplasty, either a TKA or 
a UKA, was obtained from the NHS reference costs [27] 
using the same assumptions made in our previous work [50]. 
After a UKA, a second knee arthroplasty would be a TKA, 
and at a cost of £5754. However, after a TKA, a subsequent 
TKA is almost double the cost, because the implants are 
more expensive and it is technically more difficult [13]. Any 
subsequent knee arthroplasties would all be TKAs at a cost 
of £13,551. Based on clinical experiences, for the first year 
after knee arthroplasty (KA), the cost of two outpatient visits 
was included (see Table 1) [50].
It was assumed that there would be no further costs after 
the first year if patients enter the successful health states.
Mortality
Data from the UK general population lifetime tables for age-
specific mortality rates (ONS, 2014) were used, combining 
the average probability of death for men and women. As the 
cohort ages, mortality rates generally increase throughout 
the model time horizon and patients can move to the dead 
state. Patients undergoing surgery for a UKA or TKA are 
subject to a risk of mortality. To reflect this higher mortality, 
rates were obtained from a study by Mahomed et al. [44]. 
For patients undergoing a knee arthroplasty or a knee revi-
sion, the mortality rates were reported as 0.7% and 1.1%, 
respectively [44].
Results
Table 2 below presents the base-case deterministic results 
when using an OCA graft price of £12,850. The results high-
light even though OCA transplantation is more costly, it is 
also more effective than not having an OCA. The discounted 
cost per QALY (incremental cost-effectiveness ratio) is 
£4692.
The key cost driver is the cost of the graft, but over the 
lifetime horizon, there are QALYs gained from using OCA, 
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and there are cost savings later due to fewer people needing 
a TKA in the OCA arm.
Table 3 below presents the base-case deterministic results 
when using an OCA graft price of £3892.50 (€4174) based 
on costs in Spain. Even though OCA transplantation is 
slightly more costly, it provided more QALYs than not hav-
ing an OCA. The discounted incremental cost-effectiveness 
ratio is £1652.
Table 1  Base-case mean costs used in the economic model
HRG Healthcare Resource Group, CC complication and comorbidity
a Uplifted to 2016/17 prices using the Hospital and Community Health Services (HCHS) index [15]
Resource use Information Unit cost (£) Source
OCA
 Fresh OCA graft Fresh OCA including implantation (HRG code: HN23C) £15,560a [27] 
+ expert 
opinion
[27]
 Outpatient visit Consultant-led outpatient first attendance (HRG code: WF01B) £138.43a [27]
 3 post-operation visits Consultant-led outpatient follow-up attendance (HRG code: WF01A)
8 hospital visits a year (30 min each)
£335.89a [15]
 Physiotherapy £132.00
Total cost £16,166.63
Non-operative package
 Paracetamol Twice a day per year £23.21 [8]
 Ibuprofen Once a day per year £12.47 [8]
 Physiotherapy 8 hospital visits a year (30 min each) £132.00 [15]
Total cost per year £167.69
Knee arthroplasty (KA)
 First TKA (UKA or TKA) Very major knee procedures for non-trauma with CC score 0–1 (HRG code: 
HN22E)
£5754.17a [27]
 Further TKA Second TKA £13,551.05a [13]
 Outpatient visit Consultant-led outpatient FU attendance (HRG code: WF01A) £111.96a [27]
Table 2  Base-case deterministic 
cost-effectiveness results Procedure Total mean costs Total mean QALYs
Incremental costs Incremental 
QALYs
ICER (cost per 
QALY gained)
Deterministic—undiscounted
 No OCA £11,369 37.11 – – –
 OCA £23,539 41.51 £12,170 4.40 £2765
Deterministic—discounted
 No OCA £4828 17.68 – – –
 OCA £18,652 20.63 £13,824 2.94 £4692
Table 3  Deterministic cost-
effectiveness results—changing 
the cost of the graft
Procedure Total mean costs Total mean 
QALYs
Incremental costs Incremental 
QALYs
ICER (cost per 
QALY gained)
Deterministic—undiscounted
 No OCA £11,369 37.11 – – –
 OCA £14,581 41.51 £3212 4.40 £730
Deterministic—discounted
 No OCA £4828 17.68 – – –
 OCA £9694 20.63 £4867 2.94 £1652
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Sensitivity analyses
Table 4 below presents the deterministic results assuming 
that if people need a knee arthroplasty they can have it at 
45 years instead of 55 years as in our base-case model. This 
means that they have fewer years of symptoms and hence 
some QALY gain, but may have a higher TKA revision 
rate in later years. The results are in line with the base-case 
model—OCA is more costly but more effective than not hav-
ing an OCA. The discounted incremental cost-effectiveness 
ratio is £5084.
Table 5 below presents the deterministic results for revi-
sion OCA using data from Horton et al. [33]. For simplicity 
and because of the lack of data the cost-effectiveness model 
was re-run using the probabilities of OCA revision as the 
primary OCA. Again, results are in line with the base-case 
model; even though OCA is more costly, it is more effec-
tive than not having an OCA. The discounted incremental 
cost-effectiveness ratio is £6760 (nearly £2000 more than 
the base-case ICER). However, by generally accepted costs 
per QALY, this is still very good value. Caveats are required. 
The study by Horton et al. is small, and comes from one 
of the world centres of excellence in OCA. But even if the 
ICER was trebled, it would still fall below the threshold used 
by NICE in the UK as a guide to value for money.
Discussion
The results of OCA are generally good. In most cases, there 
are no other satisfactory options, because most subjects are 
too young for knee arthroplasty.
In all scenarios, OCA was cost-effective and sensitivity 
analyses confirmed the robustness of the model. The key 
cost driver was the cost of the graft but OCA was still cost-
effective using the highest price.
The model does have a number of limitations. First, there 
were no long-term data on utilities, associated with OCA 
survival or failure. Second, our clinical experience for data 
on some resources was used in the model, for example, 
the number of post-operation outpatient visits and for the 
components of the non-operative package. Practice and, 
therefore, costs may vary. Finally, no account was taken of 
any costs to patients such as time off work and loss of pay 
(productivity).
However, the base-case cost per QALY of £4692 is con-
siderably below the threshold of £20,000 commonly used by 
NICE, so even if some of the estimates were incorrect and 
the true ICER was twice that, OCA would still be highly 
cost-effective.
An arm with metal patches was considered, but it was 
decided that these were still experimental with insufficient 
data. A high revision rate was reported with the Hemi-
CAP-Wave patch [39]. However, Becher and Cantillier [6] 
reviewed five other studies, wherein the revision rate was 
only about 10%. They reported the results of 169 HemiCAP 
implants, most successful. However, follow-up KOOS scores 
Table 4  Deterministic cost-
effectiveness results—knee 
arthroplasty at 45 years
Procedure Total mean costs Total mean 
QALYs
Incremental costs Incremental 
QALYs
ICER (cost per 
QALY gained)
Deterministic—undiscounted
 No OCA £10,891 38.20 – – –
 OCA £23,423 42.02 £12,532 3.82 £3283
Deterministic—discounted
 No OCA £5629 18.24 – – –
 OCA £18,910 20.85 £13,282 2.61 £5084
Table 5  Deterministic cost-
effectiveness results—survival 
rates from Horton et al. for 
second revision
Procedure Total mean costs Total mean 
QALYs
Incremental costs Incremental 
QALYs
ICER (cost per 
QALY gained)
Deterministic—undiscounted
 No OCA £11,369 37.11 – – –
 OCA £25,601 40.18 £14,231 3.07 £4634
Deterministic—discounted
 No OCA £4828 17.68 – – –
 OCA £19,710 19.88 £14,882 2.20 £6760
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were given but not baseline ones, so the amount of benefit 
cannot be determined.
Data on a more recent device, the second version of the 
Episealer, are as yet sparse, with two published accounts 
with ten [61] and two [6] patients. However, such patches 
may be an option in future once more data are available. One 
problem with assessing such devices is that they continue 
to evolve and long-term results may come from superseded 
versions.
Conclusions
Osteochondral allograft transplantation appears highly 
cost-effective.
If a first OCA fails, a second, revision OCA also appears 
cost-effective, but this is based on only one small study.
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